Elucidation of the potential roles of matrix metalloproteinases in skeletal biology by Krane, Stephen M
2 MMP = matrix metalloproteinase; PCR = polymerase chain reaction; r/r = collagenase-resistant homozygote.
Arthritis Research and Therapy    Vol 5 No 1 Krane
Introduction
In a recent review in Arthritis Research, Murphy et al.
emphasized the importance of degradative processes in
joint tissue destruction in various forms of arthritis [1].
They presented aspects of the background biochemistry
of the matrix metalloproteinases (MMPs) as ‘major players’
in the physiological turnover of the extracellular matrix and
in the pathological destruction in disease. Specific
inhibitors were introduced as potential therapy for arthritis,
based on the potential roles of MMPs even though they
were directed at downstream events.
Despite phenomenal advances in this area, it is still neces-
sary to establish the importance of MMPs in processes
such as normal embryonic development and adult tissue
remodeling. This is essential to targeting a specific gene
product whose function is thought to be critical in patho-
logical events (e.g. degradation of bone and soft tissue
extracellular matrices), in disorders such as osteoarthritis
and rheumatoid arthritis. There are several approaches to
establish that a MMP has the postulated biological func-
tion in arthritis. It is not sufficient only to demonstrate the
presence of the MMP in tissue extracts or by immunohis-
tochemistry in tissue sections, or to find elevated levels of
mRNA in extracted RNA by northern hybridization, by
quantitative PCR or by in situ hybridization in tissue sec-
tions. The identification in affected tissues of the specific
cleavage product of a MMP-catalyzed reaction provides
better evidence for an in vivo function. For example, using
antibodies directed against the collagenase cleavage site
in collagens, positive staining has been found for cleavage
products of type I collagen in bone and of type II collagen
in cartilage [2,3]. The expected effect of a specific enzyme
inhibitor drug supports the role of the enzyme, although in
the case of MMP inhibitors the specificity in vivo is yet to
be established [4]. The demonstration of the expected
phenotype that results from a spontaneous mutation in a
MMP gene in humans or animals or from the targeted
manipulation of a MMP gene in mice would provide the
most compelling evidence.
The report of the mutation in the gene encoding MMP-2
(gelatinase A or 72 kDa gelatinase) in a human skeletal
disorder is therefore of great interest [5,6]. There are
several forms of osteolysis in humans that have a genetic
basis. For example, a focal form (familial expansile osteoly-
sis that maps to chromosome 18q21.2-21.3) appears to
be explained by a mutation in the receptor activator of
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nuclear factor-κB gene that encodes constitutive activa-
tion and excessive osteoclastic bone resorption [7]. In a
more generalized disorder of osteolysis, Whyte et al.
recently identified the homozygous deletion of the gene on
chromosome 8q24.2, TNFRSF11B, that encodes osteo-
protegerin, a ‘bone protector’ [8].
More pertinent to the MMP field, Martignetti and col-
leagues described a form of multicentric osteolysis with
tarsal and carpal bone resorption, accompanied by severe
arthritis, osteoporosis, subcutaneous nodules and a dis-
tinctive facies, in several members of large, consan-
guineous Saudi Arabian families [5,6]. They localized the
gene to 16q12-21 and demonstrated two family-specific
mutations in the gene in the region that encodes MMP-2.
In one family, there was a nonsense mutation that pre-
dicted the replacement of a tyrosine by a stop codon
(Y244X). In another family, there was a missense mutation
that predicted the substitution of an arginine by a histidine
(R101H). In affected members of both families there was
no MMP-2 activity detected in serum by gelatin zymogra-
phy, in contrast to measurable levels in unaffected
members. Although it is clear that affected individuals with
this syndrome have decreased function of MMP-2, the
clinical phenotype is not yet explained.
We still do not know precisely what role MMP-2 plays in
human biological processes. In vitro MMP-2 can cleave
type I and type IV collagens, but it is not known whether
these are substrates for MMP-2 in vivo. In this regard, it
should be appreciated that most of the MMPs were
named after they were shown to act on a particular protein
substrate in vitro, but such proteolysis may not be the bio-
logical function of the enzyme. Indeed, the null mutation in
MMP-2 engineered in mice results in a very mild pheno-
type, manifested mainly by a decrease in bone length [9].
It has been speculated [10] that the function of MMP-2
might overlap with that of MMP-14 (MT1-MMP, a mem-
brane-bound MMP); the engineered loss-of-function muta-
tion of MMP-14 [11,12] is associated with skeletal
defects considered to partially resemble those of the
patients with the multicentric osteolysis syndrome. Most
MMP-14–/– mice die when they are only a few weeks of
age, however, and the pathogenesis and nature of the
abnormalities in bone and cartilage in the mice that survive
is not yet clearly established. Whatever the mechanisms
to account for the abnormalities, the observations in multi-
centric osteolysis are important for the field since they
comprise the first demonstration of a spontaneous muta-
tion in a MMP gene resulting in a human disease. We look
forward to descriptions of mutations and the resultant
phenotype in other MMP genes.
Our group has also taken advantage of mouse models to
further explore potential roles of MMPs in vivo. The first of
these models is the collagenase-resistant (r) mouse, tar-
geting mutations in Col1a1 that encode amino acid sub-
stitutions around the collagenase cleavage site in the α1(I)
chain of type I collagen [13–15]. The type I collagen
extracted from the skin and tendons of homozygote (r/r)
mice is not cleaved in the helical domain by MMP-13 or
other collagenolytic MMPs. The r/r mice do not mount a
normal osteoclast-mediated bone-resorptive response to
parathyroid hormone, an inducer of bone resorption in vivo
[16]. It had been hypothesized, based on published
studies of osteoclast attachment and pit formation in in
vitro assays, that collagenase produced by osteoblasts in
remodeling bone acts on a layer of hypomineralized colla-
gen on bone surfaces to permit osteoclasts to attach
[17,18] and then resorb in the low-pH extracellular envi-
ronment through action of the cysteine proteinase, cathep-
sin K [19]. There are other possible explanations, however,
for the defect in bone resorption in the r/r mice, including
a role for collagenase in osteoclast survival. The r/r mice
also develop increased new bone, paradoxically in the
presence of osteoblast and osteocyte apoptosis [20].
The second mouse model developed in our laboratory,
descriptions of which have so far only appeared as
abstracts [21,22], is the targeted disruption of the MMP-
13 gene. The strategy employed involved the deletion of
the critical zinc-binding region in the catalytic domain that
resulted in markedly decreased transcription of the MMP-
13 gene and no apparent translation. Recombinant MMP-
13 lacking this catalytic domain has no enzymatic activity.
The MMP-13–/– mice are fertile, and they grow and survive
normally. The major developmental phenotype includes
widened growth plates of long bones with increased
chondrocyte proliferation and thickness of the hyper-
trophic zones. There are also striking alterations in bone
remodeling seen as the mice mature. Bone resorption is
reduced due to disordered osteoclast function, and bone
deposition is increased ascribable to increased generation
of osteoblasts.
Conclusion
MMP-13 has critical roles in embryonic development and
remodeling of the skeleton in mice. These roles are
reflected in the collagenase-mediated destruction of bone
and cartilage in several forms of human inflammatory joint
disease. Understanding precisely how MMP-13 functions
will permit design of different approaches to dealing with
these vents in arthritis.
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